| Name | Title | Contact Details |
|---|
Jennerex Biotherapeutics is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on bringing life saving treatment to millions of people affected by acute central nervous system conditions -- including stroke and traumatic brain injury as well as other ischemic injuries and neurological disorders such as subarachnoid hemorrhage and spinal cord injury.
The Flowr Corporation is a global cannabis company that exists to cultivate better people, plants and products. Based in Toronto, we operate globally in Canada, Europe and Australia. In Canada, our operating campus in Kelowna, BC is situated in the Okanagan Valley, an epicentre of cannabis cultivation. This campus produces recreational and medicinal cannabis from a purpose-built, GMP-designed indoor cultivation facility, an outdoor and greenhouse cultivation site, and (soon to open) state-of-the-art R&D facility. Internationally, The Flowr Corporation will meet growing global medicinal cannabis demand through its subsidiary Holigen. Licensed to cultivate in Portugal, Holigen will operate GMP-designed cultivation facilities in both Portugal and Australia. Our goal is to be the #1 choice of consumers and patients alike, and our established experts in cannabis cultivation, regulated industries and consumer goods aim to meet that goal responsibly, everywhere we operate.
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
For more than 235 years, Takeda has been serving society with innovative medicines, helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest. Our mission is simple: we strive toward better health for patients worldwide through leading innovation in medicine. This mission: • Drives our research and development of prescription drugs • Promotes our commitment to social responsibility • Marks our growth and success At Takeda, our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world. Our robust product pipeline is focused on treating serious diseases and disorders, including bone and joint disorders, cardiovascular disease, central nervous system disorders, chronic kidney disease, diabetes, gastroenterology, gynecological disorders and infectious disease.